Enlivex (ENLV) Other financing activities (2013 - 2025)
Enlivex (ENLV) posted quarterly Other financing activities of $9.8 million for Q4 2025, up 680.94% year-over-year from $1.3 million in Q4 2024, and up 2693.18% quarter-over-quarter from $352000.0 in Q3 2025.
Enlivex (ENLV) Other financing activities (2013 - 2025) Analysis & Trends
Enlivex's Other financing activities history runs 12 years deep, the most recent figure standing at $9.8 million for Q4 2025.
- In Q4 2025, Other financing activities rose 680.94% year-over-year to $9.8 million; the TTM figure through Dec 2025 stood at $10.4 million (up 60.9% YoY), while the FY2025 annual figure was $10.4 million, up 60.9% from the prior year.
- Other financing activities for Q4 2025 stood at $9.8 million, up from $352000.0 in the prior quarter.
- The five-year high for Other financing activities was $13.5 million in Q1 2023, with the low at -$13.2 million in Q2 2023.
- The 5-year median for Other financing activities is $250000.0 (2024), against an average of $1.5 million.
- Peak annual rise in Other financing activities reached 26990.0% in 2023, while the deepest fall reached 26470.0% in 2023.
- Enlivex's Other financing activities stood at $7.6 million in 2021, then tumbled by 99.34% to $50000.0 in 2022, then tumbled by 26470.0% to -$13.2 million in 2023, then soared by 109.55% to $1.3 million in 2024, then soared by 680.94% to $9.8 million in 2025.
- Business Quant data shows ENLV's Other financing activities at $9.8 million in Q4 2025, $352000.0 in Q3 2025, and -$2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.83 Mn |
| Dec 31, 2025 | 9.83 Mn |
| Sep 30, 2025 | 352,000.00 |
| Sep 30, 2025 | 352,000.00 |
| Jun 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Mar 31, 2025 | 2.48 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 250,000.00 |
| Sep 30, 2024 | 250,000.00 |
| Jun 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Jun 30, 2023 | -13.19 Mn |
| Jun 30, 2023 | -13.19 Mn |
| Mar 31, 2023 | 13.55 Mn |
| Mar 31, 2023 | 13.55 Mn |